Isolated Systolic Hypertension (ISH): Treatment

Definition & Pathophysiology

Lifestyle Modifications (First Step for All)

• Sodium restriction (< 2.3 g/day)
• Weight reduction if overweight
• DASH diet
• Regular aerobic exercise
• Smoking cessation
• Moderation of alcohol intake

Pharmacological Treatment

First-Line Agents

• Thiazide diuretics are often preferred as first-line: the landmark SHEP trial demonstrated that low-dose chlorthalidone (± atenolol or reserpine as step-up) significantly reduced stroke and CV events in elderly ISH patients.
• Long-acting CCBs (e.g., amlodipine) are effective in lowering BP and reducing cardiovascular events in elderly patients with ISH and may be a preferred option in this group — Goodman & Gilman's Pharmacological Basis of Therapeutics.
• ACE inhibitors are recommended for the elderly without particular comorbidities as second-line agents, and are first-line when CKD or diabetes coexists (Swanson's Family Medicine Review).

Combination Therapy

• Thiazide + ACE inhibitor/ARB
• Thiazide + CCB
• ACE inhibitor + CCB (e.g., perindopril + amlodipine — shown superior to atenolol + HCTZ in ASCOT-BPLA)

Blood Pressure Targets in ISH

• General target: SBP < 140 mmHg
• Elderly (≥ 80 years): SBP 140–150 mmHg is acceptable per earlier guidelines; more intensive targets (< 130 mmHg) may provide additional benefit if well tolerated (SPRINT data)
• Critical caveat — J-curve: Excessive DBP lowering must be avoided. The relationship between DBP and CV mortality follows a J-curve. JNC 7 recommends a minimum post-treatment DBP of 60 mmHg (or 65 mmHg in known CAD), as too-low diastolic pressures compromise coronary perfusion — Brenner & Rector's The Kidney.
• Both JATOS and VALISH trials found no additional benefit of targeting SBP < 140 mmHg vs. < 150 mmHg in elderly Japanese patients with ISH.

Special Populations

Agents to Avoid / Use Cautiously

• Short-acting dihydropyridines (immediate-release nifedipine): no role in hypertension management
• High-dose thiazides: risk of hypokalemia, hyperuricemia, glucose intolerance
• Beta-blockers: not preferred as first-line in isolated ISH without compelling indication (may mask hypoglycemia in insulin-dependent DM; peripheral vasoconstriction worsens PVD)
• Reserpine: historically used (SHEP trial as alternative), but no longer recommended due to CNS side effects (depression risk) given availability of superior agents

Key Evidence Base

Summary Algorithm

1. Lifestyle modification for all
2. SBP 140–159 mmHg: Start monotherapy — thiazide diuretic or long-acting CCB (reduce doses in elderly)
3. SBP ≥ 160 mmHg: Consider dual therapy from the outset
4. Comorbidities guide choice of additional agents (ACE inhibitor/ARB for CKD/DM; beta-blocker for CAD)
5. Monitor DBP: avoid dropping below 60 mmHg (65 mmHg if CAD present)
6. Target: SBP < 140 mmHg; consider < 130 mmHg if young/tolerated; SBP 140–150 mmHg acceptable in frail elderly ≥ 80 years

Sources: Swanson's Family Medicine Review; Goodman & Gilman's Pharmacological Basis of Therapeutics; Brenner & Rector's The Kidney; Comprehensive Clinical Nephrology, 7e; Brunström et al. Blood Press 2023 [PMID 37395100]; Thomopoulos J Hypertens 2023 [PMID 37909131]

1. Dumping-related postprandial hypotension — antihypertensives potentiate the vasodilatory GI hormone surge that causes early dumping; BP measurements must be pre-prandial
2. Vagotomy-related baroreceptor impairment — autonomic blunting increases orthostatic hypotension risk; check standing BP at every visit
3. Drug absorption alteration — gastric reservoir loss changes dissolution and transit; avoid extended-release formulations, favor immediate-release preparations (ramipril capsules, standard amlodipine tablets)